October 20, 2020 07:48 AM EDT

Oncology research mid-pandemic: Challenges may bring durable innovation

Kari Oakes

Though clinical research, in general, has been challenged during the COVID-19 pandemic, oncology trials “have several unique considerations due to disease severity, regimen complexity, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Oncology research mid-pandemic: Challenges may bring durable innovation

Kari Oakes

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck pays $30M to buy ‘chameleon’ approach to deadly brain cancers

Eye drop maker to merge with a retinal gene therapy startup from Spark co-founder

UK’s price watchdog says Lilly’s Alzheimer’s drug is too costly for broad uptake

Corrected: Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

On­col­o­gy re­search mid-pan­dem­ic: Chal­lenges may bring durable in­no­va­tion

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Oncology research mid-pandemic: Challenges may bring durable innovation